Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Amgen India investment totals $200 million through 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
No safety signals related to the vaccine candidate were identified
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Subscribe To Our Newsletter & Stay Updated